Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and Anemia

November 9, 2026 updated by: Bing Han, Peking Union Medical College Hospital

Gecacitinib Combined With Luspatercept in Patients With Myelofibrosis and Anemia: A Single-center, Prospective, Single-arm Study

This single-center, prospective, single-arm study aims to evaluate the efficacy and safety of gecacitinib combined with luspatercept in patients with myelofibrosis and anemia who have not previously received a Janus kinase inhibitor. Participants will receive oral gecacitinib and subcutaneous luspatercept.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

31

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Age 18 years or older.
  2. Confirmed primary myelofibrosis according to the 2016 World Health Organization diagnostic criteria, or post-polycythemia vera or post-essential thrombocythemia myelofibrosis according to the International Working Group for Myeloproliferative Neoplasms Research and Treatment diagnostic criteria.
  3. Intermediate-2 or high-risk disease according to the Dynamic International Prognostic Scoring System (DIPSS) or DIPSS-plus, or intermediate-1-risk disease with hepatosplenomegaly that is unresponsive to existing treatment and requires treatment.
  4. No previous treatment with a Janus kinase inhibitor.
  5. Discontinuation of other myelofibrosis treatments, such as interferon or hydroxyurea, immunosuppressants, corticosteroids, and growth factors such as erythropoietin, for at least 2 weeks or 6 half-lives before study treatment.
  6. Splenomegaly, with the spleen palpable 5 cm below the left costal margin.
  7. Hemoglobin below 100 g/L, with or without red blood cell transfusion dependence.
  8. Platelet count of at least 75 × 10^9/L.
  9. Absolute neutrophil count of at least 1.0 × 10^9/L.
  10. Peripheral blood blasts of 10% or less.
  11. Eastern Cooperative Oncology Group performance status of 0-2 and a life expectancy of more than 6 months.
  12. Ability to independently provide written informed consent.

Exclusion Criteria:

  1. Clinically significant anemia associated with iron, vitamin B12, or folate deficiency; autoimmune or hereditary hemolytic anemia; gastrointestinal bleeding; or thalassemia.

  2. Active infection.

  3. A history of malignancy within the previous 5 years, except for cured basal cell carcinoma of the skin or cervical carcinoma in situ.

  4. Significant hepatic or renal dysfunction, or dysfunction of another major organ.

  5. Other serious conditions that, in the investigator's judgment, may affect participant safety or compliance, including:

    • Uncontrolled diabetes mellitus, with blood glucose above 250 mg/dL or 13.9 mmol/L.
    • Hypertension that cannot be controlled to a systolic blood pressure below 160 mmHg and a diastolic blood pressure below 100 mmHg despite combination antihypertensive treatment.
    • Peripheral neuropathy of grade 2 or higher according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.
  6. Previous splenectomy.

  7. Previous treatment with any transforming growth factor-beta ligand inhibitor.

  8. Pregnancy or breastfeeding, women planning pregnancy during the study, or men with near-term plans to father a child.

  9. Suspected hypersensitivity to gecacitinib, luspatercept, or drugs of the same class.

  10. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Gecacitinib + Luspatercept

gecacitinib 100 mg orally twice daily, combined with luspatercept at an initial dose of 1.0 mg/kg subcutaneously every 3 weeks

Gecacitinib will be administered orally at 100 mg twice daily in the fasting state. Dose adjustments will be based primarily on platelet counts and absolute neutrophil counts. Gecacitinib will be interrupted if the platelet count falls below 50 × 10^9/L and may be resumed when the platelet count recovers to at least 50 × 10^9/L.

Luspatercept will be administered by subcutaneous injection at an initial dose of 1.0 mg/kg every 3 weeks. The dose may be adjusted according to blood counts, up to a maximum of 1.75 mg/kg. Treatment may be interrupted if the predose hemoglobin level is at least 120 g/L or if hemoglobin increases rapidly by more than 20 g/L.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Participants Achieving an Anemia Response
Time Frame: 24 week

Anemia response is defined as conversion from red blood cell transfusion dependence at baseline to transfusion independence, or an increase in hemoglobin of at least 20 g/L in participants who do not require red blood cell transfusions and have a baseline hemoglobin level of 100 g/L or lower.

24 week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Participants With a Sustained Increase in Mean Hemoglobin of at Least 1.0 g/dL Without Transfusion
Time Frame: 24 week

Percentage of participants achieving an increase in mean hemoglobin of at least 1.0 g/dL from baseline for at least 12 consecutive weeks without red blood cell transfusions.

24 week
Time to Anemia Response
Time Frame: week 24

Time from the first dose of study treatment to the first documented anemia response.

week 24
Duration of Anemia Response
Time Frame: week 24

The longest continuous duration of anemia response among participants who achieve an anemia response.

week 24
Change From Baseline in Red Blood Cell Transfusion Amount and Frequency
Time Frame: week 24

Changes from baseline in the amount and frequency of red blood cell transfusions during study treatment.

week 24
Change From Baseline in Hemoglobin
Time Frame: weeks 4, 8, 12, 16, 20, and 24

Change in hemoglobin concentration, measured in g/L, from baseline at scheduled treatment-period visits.

weeks 4, 8, 12, 16, 20, and 24
SVR35
Time Frame: week 12 and 24

Percentage of participants achieving a reduction in spleen volume of at least 35% from baseline.

week 12 and 24
DoMSR
Time Frame: week 24

Time from the first documented reduction in spleen volume of more than 35% from baseline to the first subsequent assessment showing a reduction of less than 35% from baseline.

week 24
MPN-SAF TSS
Time Frame: weeks 4, 8, 12, 16, 20, and 24

Percentage of participants achieving a reduction of at least 50% from baseline in the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS).

weeks 4, 8, 12, 16, 20, and 24
Reduction in Fatigue Score
Time Frame: week 24

Percentage of participants achieving a reduction of at least 50% from baseline in fatigue symptom score.

week 24
Adverse Events
Time Frame: From the first dose through 28 days after the last dose.

Incidence and severity of adverse events, including events that develop or worsen during treatment and events occurring after treatment that are considered related to the study drugs by the investigator. Serious adverse events and adverse events leading to treatment interruption or discontinuation will also be recorded.

From the first dose through 28 days after the last dose.
PFS
Time Frame: 12 month

Time from the first dose of study treatment to disease progression or death from any cause, whichever occurs first.

12 month
OS
Time Frame: 12 month

Time from the first dose of study treatment to death from any cause.

12 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

December 1, 2028

Study Completion (Estimated)

December 1, 2029

Study Registration Dates

First Submitted

November 9, 2026

First Submitted That Met QC Criteria

November 9, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 9, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • K11529

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.